Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 34 |
| List of Tables | 30 | 5 |
| List of Figures | 35 | 1 |
| Introduction | 36 | 1 |
| Global Markets Direct Report Coverage | 36 | 1 |
| Kidney Cancer (Renal Cell Cancer) Overview | 37 | 1 |
| Therapeutics Development | 38 | 2 |
| Pipeline Products for Kidney Cancer (Renal Cell Cancer) Overview | 38 | 1 |
| Pipeline Products for Kidney Cancer (Renal Cell Cancer) Comparative Analysis | 39 | 1 |
| Kidney Cancer (Renal Cell Cancer) Therapeutics under Development by Companies | 40 | 11 |
| Kidney Cancer (Renal Cell Cancer) Therapeutics under Investigation by Universities/Institutes | 51 | 2 |
| Kidney Cancer (Renal Cell Cancer) Pipeline Products Glance | 53 | 4 |
| Late Stage Products | 53 | 1 |
| Clinical Stage Products | 54 | 1 |
| Early Stage Products | 55 | 1 |
| Unknown Stage Products | 56 | 1 |
| Kidney Cancer (Renal Cell Cancer) Products under Development by Companies | 57 | 18 |
| Kidney Cancer (Renal Cell Cancer) Products under Investigation by Universities/Institutes | 75 | 2 |
| Kidney Cancer (Renal Cell Cancer) Companies Involved in Therapeutics Development | 77 | 146 |
| 4SC AG | 77 | 1 |
| AbbVie Inc. | 78 | 1 |
| Acceleron Pharma, Inc. | 79 | 1 |
| Advanced Cancer Therapeutics | 80 | 1 |
| Advaxis, Inc. | 81 | 1 |
| Advenchen Laboratories, LLC | 82 | 1 |
| Alethia Biotherapeutics Inc. | 83 | 1 |
| Altor BioScience Corporation | 84 | 1 |
| Ambrx, Inc. | 85 | 1 |
| Amgen Inc. | 86 | 1 |
| Ampio Pharmaceuticals, Inc. | 87 | 1 |
| Apcure SAS | 88 | 1 |
| APEIRON Biologics AG | 89 | 1 |
| arGEN-X BV | 90 | 1 |
| Argos Therapeutics, Inc. | 91 | 1 |
| ArQule, Inc. | 92 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 93 | 1 |
| Astellas Pharma Inc. | 94 | 1 |
| AstraZeneca Plc | 95 | 1 |
| ATLAB Pharma SAS | 96 | 1 |
| Aurigene Discovery Technologies Limited | 97 | 1 |
| Bayer AG | 98 | 1 |
| Berg LLC | 99 | 1 |
| BIND Therapeutics, Inc. | 100 | 1 |
| Bio-Cancer Treatment International Limited | 101 | 1 |
| BIOCAD | 102 | 1 |
| Bionomics Limited | 103 | 1 |
| Bionovis SA | 104 | 1 |
| Boehringer Ingelheim GmbH | 105 | 1 |
| Boston Biomedical, Inc. | 106 | 1 |
| Bristol-Myers Squibb Company | 107 | 1 |
| Caladrius Biosciences, Inc. | 108 | 1 |
| Calithera Biosciences, Inc. | 109 | 1 |
| CASI Pharmaceuticals Inc. | 110 | 1 |
| Celgene Corporation | 111 | 1 |
| Cellceutix Corporation | 112 | 1 |
| Celldex Therapeutics, Inc. | 113 | 1 |
| Celltrion, Inc. | 114 | 1 |
| Cellular Biomedicine Group, Inc. | 115 | 1 |
| Cerulean Pharma, Inc. | 116 | 1 |
| Chipscreen Biosciences Ltd | 117 | 1 |
| Clonz Biotech Private Limited | 118 | 1 |
| Coare Biotechnology, Inc. | 119 | 1 |
| Coherus BioSciences, Inc. | 120 | 1 |
| Corcept Therapeutics Incorporated | 121 | 1 |
| Corvus Pharmaceuticals, Inc. | 122 | 1 |
| Cytune Pharma SAS | 123 | 1 |
| Dr. Reddy's Laboratories Limited | 124 | 1 |
| Ecrins Therapeutics SAS | 125 | 1 |
| EirGenix Inc. | 126 | 1 |
| Eisai Co., Ltd. | 127 | 1 |
| Eli Lilly and Company | 128 | 1 |
| Esperance Pharmaceuticals, Inc. | 129 | 1 |
| Exelixis, Inc. | 130 | 1 |
| F. Hoffmann-La Roche Ltd. | 131 | 1 |
| Gene Techno Science Co., Ltd. | 132 | 1 |
| Genor BioPharma Co., Ltd. | 133 | 1 |
| GenSpera, Inc. | 134 | 1 |
| GlaxoSmithKline Plc | 135 | 1 |
| Glycotope GmbH | 136 | 1 |
| HEC Pharm Co., Ltd. | 137 | 1 |
| Horizon Pharma Plc | 138 | 1 |
| Hutchison MediPharma Limited | 139 | 1 |
| Immatics Biotechnologies GmbH | 140 | 1 |
| Immune Design Corp. | 141 | 1 |
| Immunicum AB | 142 | 1 |
| ImmunoFrontier, Inc. | 143 | 1 |
| ImmunoGen, Inc. | 144 | 1 |
| Immunomedics, Inc. | 145 | 1 |
| Incuron, LLC | 146 | 1 |
| Incyte Corporation | 147 | 1 |
| Innate Immunotherapeutics Ltd | 148 | 1 |
| Johnson &Johnson | 149 | 1 |
| KAHR medical Ltd. | 150 | 1 |
| Karyopharm Therapeutics, Inc. | 151 | 1 |
| KineMed, Inc. | 152 | 1 |
| Komipharm International Co., Ltd. | 153 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 154 | 1 |
| Lead Discovery Center GmbH | 155 | 1 |
| Mabion SA | 156 | 1 |
| MacroGenics, Inc. | 157 | 1 |
| MaxiVAX SA | 158 | 1 |
| MediaPharma s.r.l. | 159 | 1 |
| MedImmune, LLC | 160 | 1 |
| Medivation, Inc. | 161 | 1 |
| Merck &Co., Inc. | 162 | 1 |
| Merck KGaA | 163 | 1 |
| Millennium Pharmaceuticals, Inc. | 164 | 1 |
| Mirati Therapeutics Inc. | 165 | 1 |
| Mirna Therapeutics, Inc. | 166 | 1 |
| Molecular Partners AG | 167 | 1 |
| Mologen AG | 168 | 1 |
| Monopar Therapeutics LLC | 169 | 1 |
| Mycenax Biotech Inc. | 170 | 1 |
| NanoSmart Pharmaceuticals, Inc. | 171 | 1 |
| Nektar Therapeutics | 172 | 1 |
| NewLink Genetics Corporation | 173 | 1 |
| Novartis AG | 174 | 1 |
| NovaTarg Therapeutics, Inc | 175 | 1 |
| Omeros Corporation | 176 | 1 |
| OncBioMune Pharmaceuticals Inc. | 177 | 1 |
| Oncobiologics, Inc. | 178 | 1 |
| Oncolys BioPharma Inc. | 179 | 1 |
| OncoMax | 180 | 1 |
| Ono Pharmaceutical Co., Ltd. | 181 | 1 |
| Panacea Biotec Limited | 182 | 1 |
| Peloton Therapeutics, Inc. | 183 | 1 |
| Pfizer Inc. | 184 | 1 |
| Pharmicell Co., Ltd. | 185 | 1 |
| Pivotal BioSciences, Inc. | 186 | 1 |
| Plexxikon Inc. | 187 | 1 |
| Prima BioMed Ltd. | 188 | 1 |
| PsiOxus Therapeutics Limited | 189 | 1 |
| Qu Biologics Inc. | 190 | 1 |
| Recombio S.L | 191 | 1 |
| Rexahn Pharmaceuticals, Inc. | 192 | 1 |
| Sanofi | 193 | 1 |
| Seattle Genetics, Inc. | 194 | 1 |
| Selvita S.A. | 195 | 1 |
| Sevion Therapeutics, Inc. | 196 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 197 | 1 |
| Sillajen Biotherapeutics | 198 | 1 |
| Sorrento Therapeutics, Inc. | 199 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 200 | 1 |
| Syndax Pharmaceuticals, Inc. | 201 | 1 |
| Synthon Holdings BV | 202 | 1 |
| Taiwan Liposome Company, Ltd. | 203 | 1 |
| Takeda Pharmaceutical Company Limited | 204 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 205 | 1 |
| Taris Biomedical LLC | 206 | 1 |
| TC BioPharm Limited | 207 | 1 |
| Teva Pharmaceutical Industries Ltd. | 208 | 1 |
| Theravectys SA | 209 | 1 |
| Threshold Pharmaceuticals, Inc. | 210 | 1 |
| Tocagen Inc. | 211 | 1 |
| TRACON Pharmaceuticals, Inc. | 212 | 1 |
| TVAX Biomedical, Inc. | 213 | 1 |
| Tyrogenex, Inc. | 214 | 1 |
| United BioPharma, Inc. | 215 | 1 |
| UroGen Pharmaceuticals, Ltd. | 216 | 1 |
| Vascular Biogenics Ltd. | 217 | 1 |
| Vault Pharma Inc. | 218 | 1 |
| Vaxeal Holding SA | 219 | 1 |
| ViiV Healthcare Limited | 220 | 1 |
| Vyriad | 221 | 1 |
| X4 Pharmaceuticals, Inc. | 222 | 1 |
| Kidney Cancer (Renal Cell Cancer) Therapeutics Assessment | 223 | 36 |
| Assessment by Monotherapy Products | 223 | 1 |
| Assessment by Combination Products | 224 | 1 |
| Assessment by Target | 225 | 19 |
| Assessment by Mechanism of Action | 244 | 11 |
| Assessment by Route of Administration | 255 | 2 |
| Assessment by Molecule Type | 257 | 2 |
| Drug Profiles | 259 | 942 |
| 4SC-205 - Drug Profile | 259 | 2 |
| Product Description | 259 | 1 |
| Mechanism of Action | 259 | 1 |
| R&D Progress | 259 | 2 |
| 9-ING41 - Drug Profile | 261 | 1 |
| Product Description | 261 | 1 |
| Mechanism of Action | 261 | 1 |
| R&D Progress | 261 | 1 |
| AB-3A4 - Drug Profile | 262 | 1 |
| Product Description | 262 | 1 |
| Mechanism of Action | 262 | 1 |
| R&D Progress | 262 | 1 |
| acalabrutinib - Drug Profile | 263 | 3 |
| Product Description | 263 | 1 |
| Mechanism of Action | 263 | 1 |
| R&D Progress | 263 | 3 |
| AdIL-24 - Drug Profile | 266 | 2 |
| Product Description | 266 | 1 |
| Mechanism of Action | 266 | 1 |
| R&D Progress | 266 | 2 |
| afatinib dimaleate - Drug Profile | 268 | 5 |
| Product Description | 268 | 1 |
| Mechanism of Action | 268 | 1 |
| R&D Progress | 268 | 5 |
| AGS-16C3F - Drug Profile | 273 | 1 |
| Product Description | 273 | 1 |
| Mechanism of Action | 273 | 1 |
| R&D Progress | 273 | 1 |
| AL-2846 - Drug Profile | 274 | 1 |
| Product Description | 274 | 1 |
| Mechanism of Action | 274 | 1 |
| R&D Progress | 274 | 1 |
| AL-3818 - Drug Profile | 275 | 2 |
| Product Description | 275 | 1 |
| Mechanism of Action | 275 | 1 |
| R&D Progress | 275 | 2 |
| AL-8326 - Drug Profile | 277 | 1 |
| Product Description | 277 | 1 |
| Mechanism of Action | 277 | 1 |
| R&D Progress | 277 | 1 |
| alpelisib - Drug Profile | 278 | 2 |
| Product Description | 278 | 1 |
| Mechanism of Action | 278 | 1 |
| R&D Progress | 278 | 2 |
| ALT-801 - Drug Profile | 280 | 2 |
| Product Description | 280 | 1 |
| Mechanism of Action | 280 | 1 |
| R&D Progress | 280 | 2 |
| ALT-803 - Drug Profile | 282 | 3 |
| Product Description | 282 | 1 |
| Mechanism of Action | 282 | 1 |
| R&D Progress | 282 | 3 |
| AM-0010 - Drug Profile | 285 | 2 |
| Product Description | 285 | 1 |
| Mechanism of Action | 285 | 1 |
| R&D Progress | 285 | 2 |
| amcasertib - Drug Profile | 287 | 2 |
| Product Description | 287 | 1 |
| Mechanism of Action | 287 | 1 |
| R&D Progress | 287 | 2 |
| ANDES-1230 - Drug Profile | 289 | 1 |
| Product Description | 289 | 1 |
| Mechanism of Action | 289 | 1 |
| R&D Progress | 289 | 1 |
| Andes-1560 - Drug Profile | 290 | 1 |
| Product Description | 290 | 1 |
| Mechanism of Action | 290 | 1 |
| R&D Progress | 290 | 1 |
| apatinib - Drug Profile | 291 | 3 |
| Product Description | 291 | 1 |
| Mechanism of Action | 291 | 1 |
| R&D Progress | 291 | 3 |
| APC-004 - Drug Profile | 294 | 1 |
| Product Description | 294 | 1 |
| Mechanism of Action | 294 | 1 |
| R&D Progress | 294 | 1 |
| APN-401 - Drug Profile | 295 | 2 |